MyAmyloidosisTeam

Both medications work by stabilizing the transthyretin protein to prevent harmful amyloid deposits. Tafamidis has been studied extensively, showing good long-term survival rates and improved quality of life for many patients. Studies have shown that nearly 96% of treated patients were alive after 10 years of follow-up Show Full Answer

Both medications work by stabilizing the transthyretin protein to prevent harmful amyloid deposits. Tafamidis has been studied extensively, showing good long-term survival rates and improved quality of life for many patients. Studies have shown that nearly 96% of treated patients were alive after 10 years of follow-up. Acoramidis (Attruby) was just approved by the FDA in 2024 for treating cardiomyopathy in wild-type ATTR amyloidosis. The main side effects reported with Acoramidis are diarrhea and mild stomach pain, which may be more tolerable than tafamidis side effects that can include allergic reactions, chest tightness, and skin rashes. Consider discussing both options with your healthcare provider to determine which medication might be most appropriate for your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

What’s the Life Expectancy With hATTR Amyloidosis?

hATTR Amyloidosis Treatments: Comparing Your Options